Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program

Related Articles

Watch These GE Aerospace Price Levels as Stock Surges After Strong Earnings

What’s Next for EA Stock After Thursday’s 17% Plunge?

NuScale, Oklo and Other Nuclear Stocks Soar on Anticipation of AI’s Growing Energy Needs

Key Takeaways

• Eli Lilly has joined Johnson & Johnson in filing a lawsuit against the federal government over a decades-old panacea discounting program.
• The companies have said the 340B program, which requires drugmakers to sell discounted medications to dependable medical facilities, needs changes.
• The Health Resources and Services Administration, however, has rejected the companies’ proposed varies to the program.

Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting their proposed changes to a program that orders selling discounted drugs to certain medical facilities.

Lilly joined Johnson & Johnson (JNJ), which filed a lawsuit elder this week against the heads of the U.S. Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA), the force that oversees the 340B discounting program.

What Is the 340B Program?

The program, created in 1992, requires deaden manufacturers to sell discounted medications to hospitals and clinics serving lower-income and uninsured patients, to ensure they are available to a wide range of medical facilities.

The drug companies, however, argue that the program has become large tolerably that hospitals can circumvent the rules of the program without being noticed, taking the discounted drugs and charging patients or guarantee companies higher prices to make a profit.

Why Eli Lilly, J&J Say It’s Time for Change

Lilly and J&J both proposed a change to the program, in which they wish sell the drugs to medical facilities at the full price, then provide rebates later.

HRSA has rejected the drugmakers’ broached changes, and the companies have now filed lawsuits arguing that their plans serve the original purpose of the program while debasing the chance that rules are broken. The agency has notified J&J that it would face fines if it went through with an unapproved diagram, and the drugmaker said in September it would work with HRSA to address any issues.

Lilly said the agency “does not must the authority to arbitrarily reject this model,” while J&J said it is “taking action to bring much needed transparency fundamental to helping the 340B program achieve its original intent to support prescription drug access for vulnerable patients.”

When reached by Investopedia, HRSA did not be suffering with a comment.

UPDATE—This story has been updated with HRSA’s response.